title: Methodological aspects of ELISA analysis of thioredoxin 1 in human plasma and cerebrospinal fluid.
abstract: Thioredoxin-1 (Trx1) is a protein antioxidant involved in major cellular processes. Increased plasma levels of Trx1 have been associated with human diseases suggesting that Trx1 is a marker for oxidative stress with putative clinical use. However, the reported mean levels of Trx1 in the control cohorts vary a hundred-fold between studies (0.8-87 ng/ml), possibly due to methodological differences between the capture ELISA used in the different studies. The aim of this study was to investigate methodological aspects related to the ELISA measurement of Trx1. ELISAs utilizing different capture and detection combinations of antibodies to Trx1 and as well as recombinant human (rh) Trx1 standards from two sources were characterized. The different ELISAs were subsequently used to measure Trx1 in human plasma and cerebrospinal fluid samples (CSF) from healthy donors and from patients with various neurological diagnoses. The Trx1 standards differed in their content of monomeric and oligomeric Trx1, which affected the ELISAs composed of different antibody combinations. Thus, the levels of Trx1 determined in human plasma and CSF samples varied depending on the antibody used in the ELISAs and on the rhTrx1 standard. Furthermore, the relevance of preventing interference by heterophilic antibodies (HA) in human plasma and CSF was investigated. The addition of a HA blocking buffer to human samples drastically reduced the ELISA signals in many samples showing that HA are likely to cause false positive results unless they are blocked. In conclusion, the study shows that the design of a Trx1 ELISA in regards to antibodies and standards used has an impact on the measured Trx1 levels. Importantly, analyses of human plasma and CSF without preventing HA interference may obscure the obtained data. Overall, the results of this study are crucial for the improvement of future studies on the association of Trx1 levels with various diseases.
authors: Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.
authors: Mathias
authors: M
authors: Lundberg
authors: Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
authors: Sophie
authors: S
authors: Curbo
authors: Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
authors: Kathrin
authors: K
authors: Reiser
authors: Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
authors: Thomas
authors: T
authors: Masterman
authors: Mabtech, Nacka, Sweden.
authors: Sten
authors: S
authors: Braesch-Andersen
authors: Mabtech, Nacka, Sweden.
authors: Irene
authors: I
authors: Areström
authors: Mabtech, Nacka, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden.
authors: Niklas
authors: N
authors: Ahlborg
mesh_terms: D000328:Adult; D000906:Antibodies / Q000276:immunology; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid / Q000175:diagnosis; D018384:Oxidative Stress; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D013879:Thioredoxins / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid
chemical_list: D000906:Antibodies; D011994:Recombinant Proteins; D013879:Thioredoxins